Compare Boston Scientific Corporation (BSX) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Oracle Corporation — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Oracle Corporation trades at $132.8 (market cap $368.53B). The key difference: Oracle Corporation is far larger — about 5.6× Boston Scientific Corporation's market cap, and Oracle Corporation pays a 1.56% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ORCL | |
|---|---|---|
Market Cap | $66.37B | $368.53B |
Sector | Health | Technology |
52-Week High | $108.14 | $328.33 |
52-Week Low | $42.63 | $127.96 |
Enterprise Value | $75.94B | $497.78B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Oracle (ORCL) trades at $131.86, down 6.27% in the last 24 hours, amid a bearish technical signal but strong fundamental performance. The company reported revenue of $57.40B in 2025 with a net income margin of 25.37%, and has beaten earnings estimates for the last three quarters. Recent news highlights Oracle's AI infrastructure growth and a pending Q2 2026 earnings report on June 10, 2026.
The outlook for Oracle is positive due to robust earnings growth and AI-driven opportunities, though risks include high debt levels and competitive pressures. Analysts maintain a bullish consensus with a $259 price target, suggesting significant upside from the current price if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
